The Rat as Experimental Model for Organ Transplantation: Technique of Rat Kidney Transplantation

2015 ◽  
pp. 167-175 ◽  
Author(s):  
Ernst Wagner
Keyword(s):  
Kidney Transplantation ◽  
Organ Transplantation ◽  
Experimental Model ◽  
Rat Kidney ◽  
Transplantation Technique

Hamster to rat kidney transplantation: technique, functional outcome and complications

1996 ◽  
Vol 24 (4) ◽  
pp. 211-216 ◽  
Author(s):  
S. Salornon ◽  
D. Steinbr�chel ◽  
B. Nielsen ◽  
E. Kemp
Keyword(s):  
Kidney Transplantation ◽  
Functional Outcome ◽  
Rat Kidney ◽  
Transplantation Technique

Adipose Tissue-Derived Stem Cells Suppress Acute Cellular Rejection by TSG-6 and CD44 Interaction in Rat Kidney Transplantation

2014 ◽  
Vol 98 (3) ◽  
pp. 277-284 ◽  
Author(s):  
Taigo Kato ◽  
Masayoshi Okumi ◽  
Masahiro Tanemura ◽  
Koji Yazawa ◽  
Yoichi Kakuta ◽  
...  
Keyword(s):  
Stem Cells ◽  
Adipose Tissue ◽  
Kidney Transplantation ◽  
Rat Kidney ◽  
Acute Cellular Rejection ◽  
Cellular Rejection

scholarly journals Microsurgical Technique of Combined Pancreas and Kidney Transplantation in Experimental Model

2015 ◽  
Vol 23 (1) ◽  
pp. 5-11
Author(s):  
E. Matevossian ◽  
◽  
I. Snopok ◽  
J. Nährig ◽  
F. Melchior ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Experimental Model ◽  
Microsurgical Technique

Immunosuppressive effects of demethylzeylasteral in a rat kidney transplantation model

2009 ◽  
Vol 9 (7-8) ◽  
pp. 996-1001 ◽  
Author(s):  
Wenping Xu ◽  
Zongming Lin ◽  
Chunxin Yang ◽  
Yongkang Zhang ◽  
Guomin Wang ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Rat Kidney ◽  
Transplantation Model

Adeno-Associated Viral Vector-Mediated Interleukin-10 Prolongs Allograft Survival in a Rat Kidney Transplantation Model

2007 ◽  
Vol 7 (5) ◽  
pp. 1112-1120 ◽  
Author(s):  
B Chen ◽  
M. H. Kapturczak ◽  
R. Joseph ◽  
J. F. George ◽  
M. Campbell-Thompson ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Viral Vector ◽  
Rat Kidney ◽  
Interleukin 10 ◽  
Allograft Survival ◽  
Transplantation Model

scholarly journals Combined Bone Marrow and Kidney Transplantation for the Induction of Specific Tolerance

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Yi-Bin Chen ◽  
Tatsuo Kawai ◽  
Thomas R. Spitzer
Keyword(s):  
Bone Marrow ◽  
Kidney Transplantation ◽  
Bone Marrow Transplantation ◽  
Organ Transplantation ◽  
Marrow Transplantation ◽  
Mixed Chimerism ◽  
Clonal Deletion ◽  
Primate Model ◽  
Hematopoietic Chimerism ◽  
Specific Tolerance

The induction of specific tolerance, in order to avoid the detrimental effects of lifelong systemic immunosuppressive therapy after organ transplantation, has been considered the “Holy Grail” of transplantation. Experimentally, tolerance has been achieved through clonal deletion, through costimulatory blockade, through the induction or infusion of regulatory T-cells, and through the establishment of hematopoietic chimerism following donor bone marrow transplantation. The focus of this review is how tolerance has been achieved following combined bone marrow and kidney transplantation. Preclinical models of combined bone marrow and kidney transplantation have shown that tolerance can be achieved through either transient or sustained hematopoietic chimerism. Combined transplants for patients with multiple myeloma have shown that organ tolerance and prolonged disease remissions can be accomplished with such an approach. Similarly, multiple clinical strategies for achieving tolerance in patients without an underlying malignancy have been described, in the context of either transient or durable mixed chimerism or sustained full donor hematopoiesis. To expand the chimerism approach to deceased donor transplants, a delayed tolerance approach, which will involve organ transplantation with conventional immunosuppression followed months later by bone marrow transplantation, has been successful in a primate model. As combined bone marrow and organ transplantation become safer and increasingly successful, the achievement of specific tolerance may become more widely applicable.

Treatment of Kaposi's sarcoma after solid organ transplantation.

1997 ◽  
Vol 15 (6) ◽  
pp. 2371-2377 ◽  
Author(s):  
F A Shepherd ◽  
E Maher ◽  
C Cardella ◽  
E Cole ◽  
P Greig ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Organ Transplantation ◽  
Combination Chemotherapy ◽  
Kaposi's Sarcoma ◽  
Solid Organ Transplantation ◽  
Kaposi’S Sarcoma ◽  
Skin Toxicity ◽  
Solid Organ ◽  
Duration Of Response ◽  
Italian Origin

PURPOSE This retrospective review of all patients who developed Kaposi's sarcoma (KS) after solid organ transplantation at a single institution was undertaken to define the clinical presentation of this malignancy in the setting of iatrogenic immunodeficiency, and to determine the most appropriate treatment for patients in this clinical setting. MATERIALS AND METHODS The records of 2,099 patients who underwent heart, lung, liver, or kidney transplantation at The Toronto Hospital between January 1, 1981 and June 30, 1995, were reviewed. Twelve patients were identified who developed biopsy-proven KS in the posttransplantation period. Five patients who had disseminated KS who had not responded to either reduction or withdrawal of immunosuppression or to local radiotherapy were treated with combination chemotherapy consisting of doxorubicin 20 to 30 mg/m2, bleomycin 10 mg/m2, and vincristine 2 mg (ABV) administered intravenously every 3 weeks. RESULTS Eight of 12 patients were male and nine were of Italian origin. KS was limited to a localized area of the skin for only six patients, all after kidney transplantation. Visceral KS was present in three patients. Four of five patients responded to ABV chemotherapy (two complete and two partial remissions). The fifth patient responded to second-line etoposide and cisplatin. The median duration of response was in excess of 13 months (range, 8+ to 45+ months). Toxicity was limited to grade 1 neurotoxicity and grade 1 skin toxicity. CONCLUSION KS is an uncommon but recognized complication of solid organ transplantation. Combination chemotherapy is a safe and effective treatment for patients with disseminated or visceral KS that fails to respond to changes in immunosuppression.

Sign in / Sign up

Export Citation Format

Share Document